Clinical trials: Nonalcoholic Steatohepatitis
Non-Alcoholic Fatty Liver Disease
Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease
The worldwide impact of obesity suggests an urgent need for solutions to decrease its burden on modern society. It has been generally understood that obesity is caused by a simple imbalance in the intake of energy in the form of…
- Trial name
- NCT04594954
- Testing
- Diet, FMT, Physical Activity
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
NASH With Fibrosis, Weight Loss
Fibrosis Reduction in Non Alcoholic Steatohepatitis
Background: Non-Alcoholic Steatohepatitis (NASH) represents one of the stages of Non-Alcoholic Fatty Liver Disease (NAFLD) with a very high risk to evolve in cirrhosis and hepato-carcinoma.
- Conditions
- NASH With Fibrosis, Weight Loss, Bariatric Surgery Candidate
- Trial name
- FRIN (NCT05798702)
- Testing
- roux -en-y- gastric bypass, intensive life style modification
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non-Alcoholic Fatty Liver Disease, Central Obesity
12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat
Obesity and non-alcoholic fatty liver disease (NAFLD) are two related growing epidemics that are becoming pressing public health concerns.
- Trial name
- NCT03912272
- Testing
- High-intensity Interval Training, Usual Care Control
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes
Quantifying Hepatic Mitochondrial Fluxes in Humans
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
- Conditions
- Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
- Trial name
- NCT05305287
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
NAFLD, Overweight and Obesity
The Role of Dietary Carbohydrate and Fat Availability in the Regulation of Hepatic Lipid Content
The purpose of this study is to investigate dietary compositions effect on liverfat measured by magnetic resonance imaging.
- Conditions
- NAFLD, Overweight and Obesity, Metabolic Syndrome, Diabetes
- Trial name
- LICARB (NCT04581421)
- Testing
- High Carb Low Fat Diet, Low Carb High Fat Diet
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Hepatic Ischemia-reperfusion Injury, Non-alcoholic Fatty Liver Disease
Mechanisms of Macrophage Polarization in HIRI in Patients With NAFLD
To better understand the occurrence of hepatic ischemia-reperfusion injury (IRI) in patients with non-alcoholic fatty liver disease (NAFLD) and the role of macrophage polarization in this process, this study will retrospectively…
- Trial name
- NCT06950710
- Testing
- NAFLD
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhifeng Gao
NAFLD, Insulin Resistance
Determination of Insulin-stimulated Hepatic Glucose Uptake by PET-CT Measurements
In the absence of excessive alcohol consumption, increased levels of fat in the liver (>5%) are diagnosed as non-alcoholic fatty liver (NAFL).
- Conditions
- NAFLD, Insulin Resistance, Overweight and Obesity
- Trial name
- ISGU (NCT04938544)
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
NASH - Nonalcoholic Steatohepatitis
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Subjects with biopsy-proven NASH will be randomly assigned in a 2:1 ratio to oral doses of namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36 weeks.
- Trial name
- NCT04697810
- Testing
- Namodenoson
- Where
- 24 sites in Bosnia and Herzegovina, Bulgaria and 4 more
- Volunteers
- 114 people
- Sponsor
- Can-Fite BioPharma
NASH - Nonalcoholic Steatohepatitis
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
- Trial name
- NATiV3 (NCT04849728)
- Testing
- IVA337
- Where
- 459 sites in United States, Argentina and 22 more
- Volunteers
- 1,000 people
- Sponsor
- Inventiva Pharma
Insulin Resistance, Hyperinsulinemia
Effect of Alpelisib in Healthy Volunteers
The goal of this clinical trial is to test a single dose of the phosphoinositide-3-kinase (PI3K) inhibitor alpelisib versus placebo in healthy volunteers.
- Conditions
- Insulin Resistance, Hyperinsulinemia, Dyslipidemias
- Trial name
- NCT05733455
- Testing
- Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Columbia University
Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease
Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!
Due to the western lifestyle, correlated with a high calorie intake and low physical activity, obesity is becoming a major health problem. All over the world obesity reaches epidemic proportions.
- Conditions
- Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01317576
- Testing
- Exercise intervention
- Where
- Netherlands
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Bram Brouwers
Non-alcoholic Steatohepatitis (NASH)
FTIH of ECC4703 in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL
- Trial name
- NCT05552274
- Testing
- ECC4703
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Eccogene
MASLD, HIV (Human Immunodeficiency Virus)
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease, is increasingly prevalent worldwide.
- Trial name
- MASLD (NCT07640880)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yinzhong Shen
Non-alcoholic Fatty Liver Disease, Fatty Liver
Study of Fish Oil to Reduce ALT Levels in Adolescents
This trial will provide preliminary data to test the hypothesis that a six-month treatment period with fish oil for overweight adolescent with mild to moderate persistent elevation of ALT levels and presence of hepatic steatosis…
- Trial name
- NCT00694746
- Testing
- Omega-3-acid ethyl esters
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Boston University
Nonalcoholic Fatty Liver Disease
Role of Exenatide in NASH-a Pilot Study
We hypothesize that exenatide (Byetta), a GLP-1 agonist administered subcutaneously for 24-28 weeks improves liver histology in diabetic patients with biopsy-proven NASH.
- Trial name
- NAFLD (NCT00650546)
- Testing
- Exenatide
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Indiana University
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease.
- Trial name
- NCT03938246
- Testing
- TVB-2640 25 mg (US), TVB-2640 50 mg (US), TVB-2640 50 mg (China)
- Where
- 23 sites in United States, China
- Volunteers
- 142 people
- Sponsor
- Sagimet Biosciences Inc.
NAFLD, Obesity, Adolescent
Impact of Weight Loss Surgery in Adolescents With NAFLD
This study will assess the impact of weight loss surgery (WLS) on non-alcoholic fatty liver disease (NAFLD) in adolescents as well as the interaction between NAFLD and cardiometabolic risk.
- Trial name
- AWLS (NCT02952170)
- Testing
- MRI
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus
Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
The aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to…
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
- Trial name
- DISTEMI (NCT05046483)
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- German Diabetes Center
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.
- Trial name
- MAESTRO-NAFLD1 (NCT04197479)
- Testing
- Resmetirom
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 1,343 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
NAFLD, NASH - Nonalcoholic Steatohepatitis
Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment
To the moment, only limited data are present on the efficacy of changes in diet composition of patients with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- 052920190055 (NCT04308980)
- Testing
- Specialized product for medical nutrition (SPP-1), individualized diet
- Where
- Russia
- Volunteers
- 45 people
- Sponsor
- Russian Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.